NCT02365597 2026-03-19
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Janssen Research & Development, LLC
Bristol-Myers Squibb
Janssen Research & Development, LLC
Hoffmann-La Roche
AstraZeneca
Astellas Pharma Inc
Novartis
US Oncology Research